SRR5088867
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.700
- INTERFERON_GAMMA_RESPONSE+0.600
- ALLOGRAFT_REJECTION+0.500
- IL6_JAK_STAT3_SIGNALING+0.300
- INFLAMMATORY_RESPONSE+0.300
- KRAS_SIGNALING_DN+0.300
- APICAL_SURFACE+0.200
- CHOLESTEROL_HOMEOSTASIS+0.200
- E2F_TARGETS+0.200
- G2M_CHECKPOINT+0.200
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.500
- PROTEIN_SECRETION-0.500
- ADIPOGENESIS-0.400
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.400
- UNFOLDED_PROTEIN_RESPONSE-0.400
- ANDROGEN_RESPONSE-0.300
- FATTY_ACID_METABOLISM-0.300
- HEME_METABOLISM-0.300
- HYPOXIA-0.300
- MTORC1_SIGNALING-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR12202481 | — | — | 0.807 |
| 2 | s_150324_1b | EPN | Supratentorial EPN | 0.804 |
| 3 | AUR-AFR5-TTP1-A-1-1-R-A743-41 | — | D | 0.801 |
| 4 | MBCProject_7544_T1_RNA | — | D | 0.788 |
| 5 | TCGA-90-A59Q-01A-11R-A26W-07 | — | cohortA1 | 0.771 |
| 6 | SRR8613797 | — | D | 0.769 |
| 7 | SRR8518351 | — | D | 0.759 |
| 8 | s0095135 | — | — | 0.750 |
| 9 | ULC0454T_S39 | — | cohortMD2 | 0.745 |
| 10 | R50 | — | — | 0.743 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.700 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.600 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.500 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.300 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.300 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.300 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.200 | Temsirolimus | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.200 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.200 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.200 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.200 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.200 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.100 | Inavolisib | — uncovered |
| COMPLEMENT | 0.100 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.100 | Cobimetinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.100 | Inavolisib | — uncovered |